Daiichi Sankyo Europe GmbH

Featured Stories

For the last ten years we as Daiichi Sankyo Europe have supported young graduates from the Ludwig-Maximilians-University in Munich (LMU). read more...

The new Daiichi Sankyo Group’s Value Report is now available! The report includes business facts & figures, information about Daiichi Sankyo’s growth potential, CSR activities and much more. read more...

Featured News

Date	Description
06/18/2019 Products	Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML	PDF
06/03/2019 Research	Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting	PDF
05/31/2019 Research	Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting	PDF
05/16/2019 Research	Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of Oncology Portfolio	PDF
05/08/2019 Research	Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need	PDF
show all

Dear User, This website provides you with information only for healthcare professionals. According to the drug promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have full access to our website. To visit our page please login.

Daiichi Sankyo
Doc Check

Support For Young Talents

Value Report 2018